Abstract:The marine natural product pateamine A (1) and its somewhat simplified designer analogue DMDA-Pat A (2) (DMDA = desmethyl-desamino) are potently cytotoxic compounds; most notably, 2 had previously been found to exhibit a promising differential in vivo activity in xenograft melanoma models, even though the ubiquitous eukaryotic initiation factor 4A (eIF4A) constitutes its primary biological target. In addition, 1 had also been identified as a possible lead in the quest for medication against cachexia, an often lethal muscle wasting syndrome affecting many immunocompromised or cancer patients. The short supply of these macrodiolides, however, rendered a more detailed biological assessment difficult. Therefore, a new synthetic approach to 1 and 2 has been devised, which centers on an unorthodox strategy for the formation of the highly isomerization-prone but essential Z, E-configured dienoate substructure embedded into the macrocyclic core. This motif was encoded in the form of a 2-pyrone ring and unveiled only immediately before macrocyclization by an unconventional iron-catalyzed ring opening/cross-coupling reaction, in which the enol ester entity of the pyrone gains the role of a leaving group. Since the required precursor was readily available by gold catalysis, this strategy rendered the overall sequence short, robust, and scalable. A surprisingly easy protecting group management together with a much improved end game for the formation of the trienyl side chain via a modern Stille coupling protocol also helped to make the chosen route practical. Change of a single building block allowed the synthesis to be redirected from the natural lead compound 1 toward its almost equipotent analogue 2. Isolation and reactivity profiling of pyrone tricarbonyliron complexes provide mechanistic information as well as insights into the likely origins of the observed chemoselectivity.

A Novel Membrane-Permeant Cadpr Antagonist Modified in the Pyrophosphate Bridge.

ChemInform Abstract: A Novel Membrane‐Permeant Cadpr Antagonist Modified in the Pyrophosphate Bridge.

Synthesis And Calcium Mobilization Activity Of Cadpr Analogues Which Integrate Nucleobase, Northern And Southern Ribose Modifications

A Novel Method for the Synthesis of Sulfur Substituted-Cyclopyrophosphate of Cadpr Analogs

Design and Synthesis of Cadpr Analogues with Simplified Ribose and Nucleobase

Synthesis And Biological Evaluation Of Novel Membrane-Permeant Cyclic Adp-Ribose Mimics: N-1-[(5 ''-O-Phosphorylethoxy)Methyl]-5 '-O-Phosphorylinosine 5 ',5 ''-Cyclicpyrophosphate (Cidpre) And 8-Substituted Derivatives

A Novel Fluorescent Cell Membrane-permeable Caged Cyclic ADP-ribose Analogue

Concise Syntheses Of Trifluoromethylated Cyclic And Acyclic Analogues Of Cadpr

Chemical Synthesis,Characterization and Biological Properties of a Novel Cyclic ADP-Ribose Analogue

Synthesis of novel ADPR analogues: substitution of pyrophosphate linkage by dipeptide

A Novel Pyridinium Modified Tetraphenylethene: AIE-activity, Mechanochromism, DNA Detection and Mitochondrial Imaging.

Trifluoromethylated Cyclic-Adp-ribose Mimic: Synthesis of 8-Trifluoromethyl-n(1)-[(5''-o-phosphorylethoxy)methyl]-5'-o-phosphorylinosine-5',5''-cyclic Pyrophosphate (8-Cf(3)-cidpre) and Its Calcium Release Activity in T Cells.

Preparation of Cyclic ADP-ribose Antagonists and Caged Cyclic ADP-ribose.

Optimization of Microwave-Assisted Synthesis of N1-ethoxymethyl-substituted Cyclic Inosine Diphosphoribose and Its Analogues

Concise Synthesis of Novel Acyclic Analogues of Cadpr with an Ether Chain As the Northern Moiety

Catalysis-Based Total Syntheses of Pateamine A and DMDA-Pat A.

Identification of a New Series of Potent Adenosine A2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson's Disease.

A Novel Class of Cyclophosphamide Prodrug: Structure-Activity Relationships of Cyclophosphamide Piperaziniums

Studies on Cyclic ADP-ribose (cadpr) Analogues: Synthesis and Calcium Release Activity

Synthesis and Agonist Activity of Cyclic ADP-ribose Analogues with Substitution of the Northern Ribose by Ether or Alkane Chains.

Structure-based design and synthesis of novel P2/P3 modified, non-peptidic β-secretase (BACE-1) inhibitors